Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Drive Commercial Preparedness
Published: January 6, 2026 | Source: GlobeNewsWire
BURLINGTON, Mass. — Fractyl Health, Inc. (NASDAQ: GUTS), a leading metabolic therapeutics firm focusing on innovative solutions to combat obesity and type 2 diabetes (T2D), announced today the appointment of Lara Smith Weber as its new Chief Financial Officer, effective January 12, 2026. This strategic hire is aimed at bolstering the company’s financial oversight and commercial readiness.
Key Responsibilities and Experience of Lara Smith Weber
In her role as Chief Financial Officer, Ms. Smith Weber will be responsible for overseeing finance, accounting, and investor relations. She will act as a vital strategic partner to Fractyl’s executive leadership team and Board of Directors.
- Over 20 years of financial leadership experience across medtech and biotech sectors.
- Proven track record in building disciplined financial organizations and managing transitions to commercial-stage operations.
- Expertise in guiding companies through complex regulatory environments and public-market challenges.
Strategic Vision for Fractyl Health
“Fractyl is entering a stage where disciplined execution and commercial preparedness are increasingly important,” said Harith Rajagopalan, M.D., Ph.D., Co-Founder and CEO of Fractyl. “Lara’s extensive experience in financial management for growth-stage healthcare organizations makes her an exceptional fit for supporting our advancement as we prepare for commercial execution.”
Previous Roles and Contributions
Before joining Fractyl, Ms. Smith Weber served as Chief Financial Officer at Inari, where she successfully completed multiple financing initiatives and enhanced the company's capital structure. Her previous experience includes leadership roles at ONWARD Medical and MorphoSys, where she significantly contributed to the organizations' transitions into commercial-stage operations.
“Fractyl is at a pivotal moment, poised to redefine treatment possibilities for metabolic diseases,” stated Ms. Smith Weber. “The shift from chronic management to durable remission offers substantial benefits for patients and the healthcare system. I am eager to join the team at this crucial juncture.”
Leadership Transition: A Farewell to Lisa Davidson
Following a decade of service, Lisa Davidson has resigned from her position as Chief Financial Officer, effective December 31, 2025. During her tenure, she significantly contributed to Fractyl's growth, including its initial public offering and the fortification of its financial practices.
“Lisa has been an invaluable partner for me and the leadership team,” emphasized Dr. Rajagopalan. “Her dedication and expertise have positioned Fractyl for its next growth phase, and we are thankful for her numerous contributions.”
About Fractyl Health
Fractyl Health is committed to pioneering transformative approaches to treat metabolic diseases, including obesity and T2D, which have become significant health challenges in the 21st century. The company aims to transition from chronic symptomatic management to durable disease-modifying therapies. Fractyl has an extensive intellectual property portfolio, comprising 35 granted U.S. patents and approximately 45 pending applications, as well as numerous international patents.
For more information, visit www.fractyl.com.
Forward-Looking Statements
This press release contains forward-looking statements based on current management expectations regarding the Company’s leadership transition and the expected contributions from its new CFO. Such statements involve risks and uncertainties that could lead to actual results differing materially.
Investors may refer to the “Risk Factors” section in our Quarterly Report on Form 10-Q filed with the SEC on November 12, 2025, for additional details on potential risks.